AbbVie partners with Iambic Therapeutics on multi-year AI drug discovery collaboration
AbbVie (ABBV) has entered into a long-term partnership with Iambic Therapeutics to develop small-molecule therapies for immunology, neuroscience, and oncology using the latter's artificial intelligence platform. The agreement aims to enhance efficiency in drug discovery by leveraging advanced AI capabilities. This collaboration reflects growing interest among pharmaceutical companies in integrating machine learning technologies to accelerate research processes and improve success rates in early-stage development. Iambic’s platform is expected to play a key role in identifying novel therapeutic candidates across multiple disease areas, potentially reducing time-to-market for new treatments.
Tickers: $ABBV
Topics: AI Drug Discovery Immunology Neuroscience Oncology Pharmaceuticals